Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma
Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC cohort, and its association with clinical endpoints and functional relevance are unclear. We used a cohort of 116 patients to fine map the 7q21...
Saved in:
Published in | Clinical cancer research Vol. 17; no. 13; pp. 4513 - 4522 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.07.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC cohort, and its association with clinical endpoints and functional relevance are unclear.
We used a cohort of 116 patients to fine map the 7q21 amplification using SNP microarrays. Prognostic significance and functional role of 7q21 amplification and its gene expression were explored.
Amplification of the 7q21 region was observed in 35% of tumors with a focal, minimal amplicon containing six genes. 7q21 amplification was associated with poor survival and analysis of gene expression identified cyclin-dependent kinase 6 (CDK6) as the only gene in the minimal amplicon whose expression was also associated with poor survival. A low-level amplification (10%) was observed at the 12q13 region containing the CDK6 homologue cyclin-dependent kinase 4 (CDK4). Both amplification and expression of CDK4 correlated with poor survival. A combined model of both CDK6 and CDK4 expressions is a superior predictor of survival than either alone. Specific knockdown of CDK4 and/or CDK6 by siRNAs shows that they are required for proliferation of EAC cells and that their function is additive. PD-0332991 targets the kinase activity of both molecules and suppresses proliferation and anchorage independence of EAC cells through activation of the pRB pathway.
We suggest that CDK6 is the driver of 7q21 amplification and that both CDK4 and CDK6 are prognostic markers and bona fide oncogenes in EAC. Targeting these molecules may constitute a viable new therapy for this disease. |
---|---|
AbstractList | Purpose: Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC cohort, and its association with clinical endpoints and functional relevance are unclear.
Experimental Design: We used a cohort of 116 patients to fine map the 7q21 amplification using SNP microarrays. Prognostic significance and functional role of 7q21 amplification and its gene expression were explored.
Results: Amplification of the 7q21 region was observed in 35% of tumors with a focal, minimal amplicon containing six genes. 7q21 amplification was associated with poor survival and analysis of gene expression identified cyclin-dependent kinase 6 (CDK6) as the only gene in the minimal amplicon whose expression was also associated with poor survival. A low-level amplification (10%) was observed at the 12q13 region containing the CDK6 homologue cyclin-dependent kinase 4 (CDK4). Both amplification and expression of CDK4 correlated with poor survival. A combined model of both CDK6 and CDK4 expressions is a superior predictor of survival than either alone. Specific knockdown of CDK4 and/or CDK6 by siRNAs shows that they are required for proliferation of EAC cells and that their function is additive. PD-0332991 targets the kinase activity of both molecules and suppresses proliferation and anchorage independence of EAC cells through activation of the pRB pathway.
Conclusions: We suggest that CDK6 is the driver of 7q21 amplification and that both CDK4 and CDK6 are prognostic markers and bona fide oncogenes in EAC. Targeting these molecules may constitute a viable new therapy for this disease. Clin Cancer Res; 17(13); 4513–22. ©2011 AACR. PURPOSE: Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC cohort, and its association with clinical endpoints and functional relevance are unclear. Experimental Design: We used a cohort of 116 patients to fine map the 7q21 amplification using SNP microarrays. Prognostic significance and functional role of 7q21 amplification and its gene expression were explored. RESULTS: Amplification of the 7q21 region was observed in 35% of tumors with a focal, minimal amplicon containing six genes. 7q21 amplification was associated with poor survival and analysis of gene expression identified cyclin-dependent kinase 6 (CDK6) as the only gene in the minimal amplicon whose expression was also associated with poor survival. A low-level amplification (10%) was observed at the 12q13 region containing the CDK6 homologue cyclin-dependent kinase 4 (CDK4). Both amplification and expression of CDK4 correlated with poor survival. A combined model of both CDK6 and CDK4 expressions is a superior predictor of survival than either alone. Specific knockdown of CDK4 and/or CDK6 by siRNAs shows that they are required for proliferation of EAC cells and that their function is additive. PD-0332991 targets the kinase activity of both molecules and suppresses proliferation and anchorage independence of EAC cells through activation of the pRB pathway. CONCLUSIONS: We suggest that CDK6 is the driver of 7q21 amplification and that both CDK4 and CDK6 are prognostic markers and bona fide oncogenes in EAC. Targeting these molecules may constitute a viable new therapy for this disease. Clin Cancer Res; 17(13); 4513-22. [copy ]2011 AACR. Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC cohort, and its association with clinical endpoints and functional relevance are unclear. We used a cohort of 116 patients to fine map the 7q21 amplification using SNP microarrays. Prognostic significance and functional role of 7q21 amplification and its gene expression were explored. Amplification of the 7q21 region was observed in 35% of tumors with a focal, minimal amplicon containing six genes. 7q21 amplification was associated with poor survival and analysis of gene expression identified cyclin-dependent kinase 6 (CDK6) as the only gene in the minimal amplicon whose expression was also associated with poor survival. A low-level amplification (10%) was observed at the 12q13 region containing the CDK6 homologue cyclin-dependent kinase 4 (CDK4). Both amplification and expression of CDK4 correlated with poor survival. A combined model of both CDK6 and CDK4 expressions is a superior predictor of survival than either alone. Specific knockdown of CDK4 and/or CDK6 by siRNAs shows that they are required for proliferation of EAC cells and that their function is additive. PD-0332991 targets the kinase activity of both molecules and suppresses proliferation and anchorage independence of EAC cells through activation of the pRB pathway. We suggest that CDK6 is the driver of 7q21 amplification and that both CDK4 and CDK6 are prognostic markers and bona fide oncogenes in EAC. Targeting these molecules may constitute a viable new therapy for this disease. |
Author | PETERS, Jeffrey H TOIA, Liana REVEILLER, Marie LITLE, Virginia R STEIN, Lincoln ISMAIL, Amin KALATSKAYA, Irina D'SOUZA, Mary PENNATHUR, Arjun LUKETICH, James D GOODING, William E ZHONGREN ZHOU GODFREY, Tony E BANDLA, Santhoshi |
AuthorAffiliation | 5 The James P. Wilmot Cancer Center, University of Rochester, Rochester, NY 4 Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 2 Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA 1 Department of Surgery, University of Rochester Medical Center, Rochester, NY 3 Ontario Institute for Cancer Research, Toronto, ON, Canada |
AuthorAffiliation_xml | – name: 2 Biostatistics Facility, University of Pittsburgh Cancer Institute, Pittsburgh, PA – name: 1 Department of Surgery, University of Rochester Medical Center, Rochester, NY – name: 5 The James P. Wilmot Cancer Center, University of Rochester, Rochester, NY – name: 4 Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA – name: 3 Ontario Institute for Cancer Research, Toronto, ON, Canada |
Author_xml | – sequence: 1 givenname: Amin surname: ISMAIL fullname: ISMAIL, Amin organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 2 givenname: Santhoshi surname: BANDLA fullname: BANDLA, Santhoshi organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 3 givenname: Jeffrey H surname: PETERS fullname: PETERS, Jeffrey H organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 4 givenname: Arjun surname: PENNATHUR fullname: PENNATHUR, Arjun organization: Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States – sequence: 5 givenname: James D surname: LUKETICH fullname: LUKETICH, James D organization: Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States – sequence: 6 givenname: Tony E surname: GODFREY fullname: GODFREY, Tony E organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 7 givenname: Marie surname: REVEILLER fullname: REVEILLER, Marie organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 8 givenname: Liana surname: TOIA fullname: TOIA, Liana organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 9 surname: ZHONGREN ZHOU fullname: ZHONGREN ZHOU organization: Department of Pathology, University of Rochester, Rochester, New York, United States – sequence: 10 givenname: William E surname: GOODING fullname: GOODING, William E organization: Biostatistics Facility, University of Pittsburgh Cancer Institute, United States – sequence: 11 givenname: Irina surname: KALATSKAYA fullname: KALATSKAYA, Irina organization: Ontario Institute for Cancer Research, Toronto, Ontario, Canada – sequence: 12 givenname: Lincoln surname: STEIN fullname: STEIN, Lincoln organization: Ontario Institute for Cancer Research, Toronto, Ontario, Canada – sequence: 13 givenname: Mary surname: D'SOUZA fullname: D'SOUZA, Mary organization: Department of Surgery, University of Rochester Medical Center, United States – sequence: 14 givenname: Virginia R surname: LITLE fullname: LITLE, Virginia R organization: Department of Surgery, University of Rochester Medical Center, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24339786$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21593195$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1u1DAUhSNURH_gEUDeILFJ8Y3_kg1SFYaCKKJCw9q6cZwZQ8ZO7UyleXscdVpgZev6u8dH-s6LEx-8LYrXQC8BRP0eqKpLyll1aUwsAUpacf6sOAMhVMkqKU7y_ZE5Lc5T-kUpcKD8RXFagWgYNOKsuF9hHA_kGkh7MKPz5Uc7Wd9bP5OvzmOyiWAitzFsfEizM-Qbxt825qnvyW2YM-hwJOutjTjZ_UKsMW7snIjzZJXCtMWNzcRVzgwGo3E-7PBl8XzAMdlXx_Oi-PlptW4_lzffr7-0Vzel4YLzEiWlkuEADQIq03TN0NNh6DrJOkAKSvSqplhJUH1dGQWy6uqmwYGhErwT7KL48JA77bud7U2uG3HUU3Q7jAcd0On_X7zb6k2414w1VCmZA94dA2K429s0651Lxo4jehv2SQNtGJdCCsioeEBNDClFOzx9A1QvzvTiQy8-dNv-yCO9OMt7b_7t-LT1KCkDb48AJoPjENEbl_5yPJdVtWR_AD3co3A |
CODEN | CCREF4 |
CitedBy_id | crossref_primary_10_1186_s12967_019_1987_z crossref_primary_10_1038_s41588_018_0331_5 crossref_primary_10_1016_j_cpet_2017_05_001 crossref_primary_10_1177_1078155218770904 crossref_primary_10_1002_gcc_21951 crossref_primary_10_1016_j_humpath_2016_10_025 crossref_primary_10_1002_mco2_55 crossref_primary_10_1158_0008_5472_CAN_11_3893 crossref_primary_10_1038_s41467_019_09179_w crossref_primary_10_1080_14737140_2019_1615889 crossref_primary_10_1038_nrclinonc_2016_26 crossref_primary_10_3390_ijms24108939 crossref_primary_10_1038_bjc_2017_209 crossref_primary_10_1097_MPA_0000000000000944 crossref_primary_10_1002_jcp_26136 crossref_primary_10_1186_s13045_017_0467_2 crossref_primary_10_1016_j_gtc_2015_02_015 crossref_primary_10_1158_1078_0432_CCR_18_1029 crossref_primary_10_1002_jcp_26613 crossref_primary_10_3390_cancers13235915 crossref_primary_10_1007_s10147_023_02299_w crossref_primary_10_1016_j_athoracsur_2012_01_064 crossref_primary_10_1038_nrdp_2017_48 crossref_primary_10_1016_j_ajpath_2015_01_008 crossref_primary_10_1016_j_trecan_2016_11_006 crossref_primary_10_1016_j_jtcvs_2017_08_029 crossref_primary_10_1016_j_pharmthera_2013_06_005 crossref_primary_10_1038_nrd4504 crossref_primary_10_1200_PO_20_00032 crossref_primary_10_18632_oncotarget_22244 crossref_primary_10_1016_j_critrevonc_2020_103199 crossref_primary_10_1016_j_bbcan_2019_05_003 crossref_primary_10_1245_s10434_012_2317_3 crossref_primary_10_3390_cells9040801 crossref_primary_10_3390_cancers14020293 crossref_primary_10_1016_j_canlet_2019_05_018 crossref_primary_10_1038_onc_2013_83 crossref_primary_10_3389_fendo_2020_00219 crossref_primary_10_1007_s11094_022_02599_x crossref_primary_10_1158_1078_0432_CCR_13_1645 crossref_primary_10_1186_1478_811X_10_41 crossref_primary_10_1111_bph_13836 |
Cites_doi | 10.1186/bcr2454 10.1016/j.ejca.2010.02.028 10.1016/j.cancergencyto.2008.08.018 10.1002/pros.2990260108 10.1158/1541-7786.105.2.2 10.1006/excr.1999.4389 10.1016/j.canlet.2009.01.006 10.1002/cncr.24987 10.1016/j.jamcollsurg.2005.12.022 10.1158/1535-7163.1427.3.11 10.1177/107327480701400313 10.1016/j.ygyno.2007.01.004 10.1016/j.cell.2004.08.002 10.1186/bcr2419 10.1158/1940-6207.CAPR-09-0265 10.1016/j.gde.2009.11.005 10.2174/138945010791591395 10.1016/j.cancergencyto.2005.11.002 10.1016/S0065-230X(10)07006-5 10.1016/j.tibs.2005.09.005 10.1159/000288295 10.1038/87872 10.1002/gcc.20570 10.1136/gut.2003.028076 10.1158/0008-5472.CAN-08-4025 10.1245/ASO.2005.12.025 10.1023/B:JOMG.0000023591.45568.77 10.1053/j.gastro.2010.01.007 10.1200/JCO.2005.02.8589 10.1158/0008-5472.CAN-09-4559 10.1124/jpet.104.073924 10.1038/sj.leu.2405028 10.1038/sj.onc.1202132 10.1038/modpathol.3800712 10.1038/onc.2008.246 10.1016/j.ijrobp.2006.08.076 10.1038/onc.2009.170 10.4161/cc.9.9.11535 10.1073/pnas.1530509100 10.1016/j.cell.2006.10.003 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS |
Copyright_xml | – notice: 2015 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 5PM |
DOI | 10.1158/1078-0432.ccr-11-0244 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | CrossRef Engineering Research Database MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 1078-0432 |
EndPage | 4522 |
ExternalDocumentID | 10_1158_1078_0432_CCR_11_0244 21593195 24339786 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01CA130853 – fundername: NCI NIH HHS grantid: R01 CA130853-01A1 – fundername: NCI NIH HHS grantid: R01 CA130853 – fundername: National Cancer Institute : NCI grantid: R01 CA130853 || CA |
GroupedDBID | --- .55 .GJ 08R 18M 1CY 29B 2FS 2WC 34G 39C 3O- 476 4H- 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 H~9 IH2 IQODW J5H KQ8 L7B LSO MVM OHT OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WHG WOQ X7M XFK XJT YKV ZA5 ZCG ZGI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 5PM |
ID | FETCH-LOGICAL-c4544-a60063af19a1a7c9b9fd0ffbb63b1a0175d780a2617d82c7162b899af3a754b53 |
ISSN | 1078-0432 |
IngestDate | Tue Sep 17 21:20:24 EDT 2024 Sat Aug 17 00:59:39 EDT 2024 Thu Nov 21 21:03:09 EST 2024 Sat Sep 28 07:48:28 EDT 2024 Sun Oct 29 17:07:16 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 13 |
Keywords | Prognosis Targeting Enzyme Targeted therapy Transferases Esophageal disease Biological marker Malignant tumor Esophagus cancer G1 Phase Treatment Cell cycle Digestive diseases Esophagus adenocarcinoma Early Cyclin dependent kinase Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4544-a60063af19a1a7c9b9fd0ffbb63b1a0175d780a2617d82c7162b899af3a754b53 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/17/13/4513.full.pdf |
PMID | 21593195 |
PQID | 1093465651 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3390776 proquest_miscellaneous_1093465651 crossref_primary_10_1158_1078_0432_CCR_11_0244 pubmed_primary_21593195 pascalfrancis_primary_24339786 |
PublicationCentury | 2000 |
PublicationDate | 2011-07-01 |
PublicationDateYYYYMMDD | 2011-07-01 |
PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2011 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 20404570 - Cell Cycle. 2010 May;9(9):1809-18 10094818 - Exp Cell Res. 1999 Apr 10;248(1):110-4 9811454 - Oncogene. 1998 Oct 29;17(17):2235-49 19216023 - Cancer Lett. 2009 Jun 18;278(2):230-40 20426765 - Curr Drug Targets. 2010 Aug;11(8):1000-17 16631473 - Cancer Genet Cytogenet. 2006 Apr 15;166(2):157-62 17300833 - Gynecol Oncol. 2007 May;105(2):462-9 19167610 - Cancer Genet Cytogenet. 2009 Feb;189(1):37-42 20651033 - Cancer Prev Res (Phila). 2010 Sep;3(9):1176-86 17055429 - Cell. 2006 Oct 20;127(2):265-75 15082921 - J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):95-104 16314645 - J Clin Oncol. 2005 Dec 1;23(34):8853-62 14985467 - Mol Cancer Res. 2004 Feb;2(2):105-14 19874578 - Breast Cancer Res. 2009;11(5):R77 19561645 - Oncogene. 2009 Aug 20;28(33):2925-39 20303741 - Eur J Cancer. 2010 May;46(7):1260-70 15304523 - J Pharmacol Exp Ther. 2005 Jan;312(1):206-13 7845865 - Prostate. 1995 Jan;26(1):35-9 15315761 - Cell. 2004 Aug 20;118(4):493-504 20060285 - Curr Opin Genet Dev. 2010 Feb;20(1):4-14 20185938 - Oncology. 2010;78(1):26-33 10919634 - Cancer Res. 2000 Jul 15;60(14):3689-95 9102208 - Cancer Res. 1997 Apr 1;57(7):1250-4 20399964 - Adv Cancer Res. 2010;107:163-224 12883005 - Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 18438866 - Genes Chromosomes Cancer. 2008 Aug;47(8):649-56 20100483 - Gastroenterology. 2010 May;138(5):1920-30 17097832 - Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):405-9 15247170 - Gut. 2004 Aug;53(8):1070-4 17989712 - Leukemia. 2008 Feb;22(2):387-92 11329054 - Nat Med. 2001 May;7(5):548-52 20354191 - Cancer Res. 2010 Apr 15;70(8):3228-38 16571425 - J Am Coll Surg. 2006 Apr;202(4):588-96; discussion 596-8 17143264 - Mod Pathol. 2007 Jan;20(1):120-9 17615536 - Cancer Control. 2007 Jul;14(3):295-304 15542782 - Mol Cancer Ther. 2004 Nov;3(11):1427-38 19435910 - Cancer Res. 2009 May 15;69(10):4443-53 11309301 - Cancer Res. 2001 Apr 15;61(8):3410-8 20067604 - Breast Cancer Res. 2009;11(6):112 16236519 - Trends Biochem Sci. 2005 Nov;30(11):630-41 20336784 - Cancer. 2010 Jun 1;116(11):2621-34 14593696 - Prog Cell Cycle Res. 2003;5:5-18 16378161 - Ann Surg Oncol. 2006 Jan;13(1):12-30 18794885 - Oncogene. 2008 Sep 18;27(41):5511-26 Ismail (2022061019512851500_bib13) 2009; 278 Fry (2022061019512851500_bib17) 2004; 3 Reichelt (2022061019512851500_bib6) 2007; 20 Niu (2022061019512851500_bib23) 2010; 11 Garcia-Echeverria (2022061019512851500_bib22) 2008; 27 Finn (2022061019512851500_bib16) 2009; 11 Nagel (2022061019512851500_bib25) 2008; 22 Mendrzyk (2022061019512851500_bib27) 2005; 23 Kim (2022061019512851500_bib33) 2006; 127 Rocha-Lima (2022061019512851500_bib21) 2007; 14 Fishel (2022061019512851500_bib43) 2005; 312 Albihn (2022061019512851500_bib19) 2010; 107 Korkola (2022061019512851500_bib18) 2010; 20 Agirre (2022061019512851500_bib36) 2009; 69 Lucas (2022061019512851500_bib37) 2004; 2 Malumbres (2022061019512851500_bib28) 2005; 30 van Dekken (2022061019512851500_bib11) 2006; 166 Wu (2022061019512851500_bib35) 2010; 9 Coley (2022061019512851500_bib44) 2007; 105 Boylan (2022061019512851500_bib15) 1999; 248 Satyanarayana (2022061019512851500_bib39) 2009; 28 Jorgensen (2022061019512851500_bib7) 2010; 78 Nakayama (2022061019512851500_bib32) 2010; 116 Cecchi (2022061019512851500_bib24) 2010; 46 DeMeester (2022061019512851500_bib1) 2006; 13 Safran (2022061019512851500_bib8) 2007; 67 Sutherland (2022061019512851500_bib31) 2004; 9 Storey (2022061019512851500_bib14) 2003; 100 Michaud (2022061019512851500_bib41) 2010; 70 Rivadeneira (2022061019512851500_bib40) 2010; 138 Malumbres (2022061019512851500_bib29) 2003; 5 Solaymani-Dodaran (2022061019512851500_bib2) 2004; 53 Malumbres (2022061019512851500_bib38) 2004; 118 Sutherland (2022061019512851500_bib42) 2009; 11 Pietras (2022061019512851500_bib5) 1998; 17 Bange (2022061019512851500_bib20) 2001; 7 Brooks (2022061019512851500_bib34) 1995; 26 Sherr (2022061019512851500_bib30) 2000; 60 Eads (2022061019512851500_bib3) 2001; 61 van Dekken (2022061019512851500_bib10) 2009; 189 Portale (2022061019512851500_bib4) 2006; 202 Gu (2022061019512851500_bib9) 2010; 3 van Dekken (2022061019512851500_bib12) 2008; 47 Costello (2022061019512851500_bib26) 1997; 57 |
References_xml | – volume: 11 start-page: 112 year: 2009 ident: 2022061019512851500_bib42 article-title: CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease publication-title: Breast Cancer Res doi: 10.1186/bcr2454 contributor: fullname: Sutherland – volume: 46 start-page: 1260 year: 2010 ident: 2022061019512851500_bib24 article-title: Targeting the HGF/Met signalling pathway in cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.02.028 contributor: fullname: Cecchi – volume: 189 start-page: 37 year: 2009 ident: 2022061019512851500_bib10 article-title: Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction publication-title: Cancer Genet Cytogenet doi: 10.1016/j.cancergencyto.2008.08.018 contributor: fullname: van Dekken – volume: 26 start-page: 35 year: 1995 ident: 2022061019512851500_bib34 article-title: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas publication-title: Prostate doi: 10.1002/pros.2990260108 contributor: fullname: Brooks – volume: 2 start-page: 105 year: 2004 ident: 2022061019512851500_bib37 article-title: Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells publication-title: Mol Cancer Res doi: 10.1158/1541-7786.105.2.2 contributor: fullname: Lucas – volume: 248 start-page: 110 year: 1999 ident: 2022061019512851500_bib15 article-title: Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression publication-title: Exp Cell Res doi: 10.1006/excr.1999.4389 contributor: fullname: Boylan – volume: 57 start-page: 1250 year: 1997 ident: 2022061019512851500_bib26 article-title: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA publication-title: Cancer Res contributor: fullname: Costello – volume: 278 start-page: 230 year: 2009 ident: 2022061019512851500_bib13 article-title: Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma publication-title: Cancer Lett doi: 10.1016/j.canlet.2009.01.006 contributor: fullname: Ismail – volume: 116 start-page: 2621 year: 2010 ident: 2022061019512851500_bib32 article-title: Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer publication-title: Cancer doi: 10.1002/cncr.24987 contributor: fullname: Nakayama – volume: 60 start-page: 3689 year: 2000 ident: 2022061019512851500_bib30 article-title: The Pezcoller lecture: cancer cell cycles revisited publication-title: Cancer Res contributor: fullname: Sherr – volume: 202 start-page: 588 year: 2006 ident: 2022061019512851500_bib4 article-title: Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2005.12.022 contributor: fullname: Portale – volume: 3 start-page: 1427 year: 2004 ident: 2022061019512851500_bib17 article-title: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.1427.3.11 contributor: fullname: Fry – volume: 14 start-page: 295 year: 2007 ident: 2022061019512851500_bib21 article-title: EGFR targeting of solid tumors publication-title: Cancer Control doi: 10.1177/107327480701400313 contributor: fullname: Rocha-Lima – volume: 105 start-page: 462 year: 2007 ident: 2022061019512851500_bib44 article-title: The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2007.01.004 contributor: fullname: Coley – volume: 61 start-page: 3410 year: 2001 ident: 2022061019512851500_bib3 article-title: Epigenetic patterns in the progression of esophageal adenocarcinoma publication-title: Cancer Res contributor: fullname: Eads – volume: 118 start-page: 493 year: 2004 ident: 2022061019512851500_bib38 article-title: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6 publication-title: Cell doi: 10.1016/j.cell.2004.08.002 contributor: fullname: Malumbres – volume: 11 start-page: R77 year: 2009 ident: 2022061019512851500_bib16 article-title: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro publication-title: Breast Cancer Res doi: 10.1186/bcr2419 contributor: fullname: Finn – volume: 3 start-page: 1176 year: 2010 ident: 2022061019512851500_bib9 article-title: Genome-wide catalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis publication-title: Cancer Prev Res (Phila) doi: 10.1158/1940-6207.CAPR-09-0265 contributor: fullname: Gu – volume: 20 start-page: 4 year: 2010 ident: 2022061019512851500_bib18 article-title: Breast cancer genomes—form and function publication-title: Curr Opin Genet Dev doi: 10.1016/j.gde.2009.11.005 contributor: fullname: Korkola – volume: 11 start-page: 1000 year: 2010 ident: 2022061019512851500_bib23 article-title: Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy publication-title: Curr Drug Targets doi: 10.2174/138945010791591395 contributor: fullname: Niu – volume: 166 start-page: 157 year: 2006 ident: 2022061019512851500_bib11 article-title: Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastro-esophageal junction publication-title: Cancer Genet Cytogenet doi: 10.1016/j.cancergencyto.2005.11.002 contributor: fullname: van Dekken – volume: 107 start-page: 163 year: 2010 ident: 2022061019512851500_bib19 article-title: MYC in oncogenesis and as a target for cancer therapies publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(10)07006-5 contributor: fullname: Albihn – volume: 30 start-page: 630 year: 2005 ident: 2022061019512851500_bib28 article-title: Mammalian cyclin-dependent kinases publication-title: Trends Biochem Sci doi: 10.1016/j.tibs.2005.09.005 contributor: fullname: Malumbres – volume: 78 start-page: 26 year: 2010 ident: 2022061019512851500_bib7 article-title: Targeted HER2 treatment in advanced gastric cancer publication-title: Oncology doi: 10.1159/000288295 contributor: fullname: Jorgensen – volume: 7 start-page: 548 year: 2001 ident: 2022061019512851500_bib20 article-title: Molecular targets for breast cancer therapy and prevention publication-title: Nat Med doi: 10.1038/87872 contributor: fullname: Bange – volume: 47 start-page: 649 year: 2008 ident: 2022061019512851500_bib12 article-title: Molecular dissection of the chromosome band 7q21 amplicon in gastroesophageal junction adenocarcinomas identifies cyclin-dependent kinase 6 at both genomic and protein expression levels publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20570 contributor: fullname: van Dekken – volume: 53 start-page: 1070 year: 2004 ident: 2022061019512851500_bib2 article-title: Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux publication-title: Gut doi: 10.1136/gut.2003.028076 contributor: fullname: Solaymani-Dodaran – volume: 69 start-page: 4443 year: 2009 ident: 2022061019512851500_bib36 article-title: Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-4025 contributor: fullname: Agirre – volume: 5 start-page: 5 year: 2003 ident: 2022061019512851500_bib29 article-title: Cell cycle deregulation: a common motif in cancer publication-title: Prog Cell Cycle Res contributor: fullname: Malumbres – volume: 13 start-page: 12 year: 2006 ident: 2022061019512851500_bib1 article-title: Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment publication-title: Ann Surg Oncol doi: 10.1245/ASO.2005.12.025 contributor: fullname: DeMeester – volume: 9 start-page: 95 year: 2004 ident: 2022061019512851500_bib31 article-title: Cyclins and breast cancer publication-title: J Mammary Gland Biol Neoplasia doi: 10.1023/B:JOMG.0000023591.45568.77 contributor: fullname: Sutherland – volume: 138 start-page: 1920 year: 2010 ident: 2022061019512851500_bib40 article-title: Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.01.007 contributor: fullname: Rivadeneira – volume: 23 start-page: 8853 year: 2005 ident: 2022061019512851500_bib27 article-title: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.02.8589 contributor: fullname: Mendrzyk – volume: 70 start-page: 3228 year: 2010 ident: 2022061019512851500_bib41 article-title: Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-4559 contributor: fullname: Michaud – volume: 312 start-page: 206 year: 2005 ident: 2022061019512851500_bib43 article-title: Effect of cell cycle inhibition on cisplatin-induced cytotoxicity publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.104.073924 contributor: fullname: Fishel – volume: 22 start-page: 387 year: 2008 ident: 2022061019512851500_bib25 article-title: Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma publication-title: Leukemia doi: 10.1038/sj.leu.2405028 contributor: fullname: Nagel – volume: 17 start-page: 2235 year: 1998 ident: 2022061019512851500_bib5 article-title: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs publication-title: Oncogene doi: 10.1038/sj.onc.1202132 contributor: fullname: Pietras – volume: 20 start-page: 120 year: 2007 ident: 2022061019512851500_bib6 article-title: Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus publication-title: Mod Pathol doi: 10.1038/modpathol.3800712 contributor: fullname: Reichelt – volume: 27 start-page: 5511 year: 2008 ident: 2022061019512851500_bib22 article-title: Drug discovery approaches targeting the PI3K/Akt pathway in cancer publication-title: Oncogene doi: 10.1038/onc.2008.246 contributor: fullname: Garcia-Echeverria – volume: 67 start-page: 405 year: 2007 ident: 2022061019512851500_bib8 article-title: Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2006.08.076 contributor: fullname: Safran – volume: 28 start-page: 2925 year: 2009 ident: 2022061019512851500_bib39 article-title: Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms publication-title: Oncogene doi: 10.1038/onc.2009.170 contributor: fullname: Satyanarayana – volume: 9 start-page: 1809 year: 2010 ident: 2022061019512851500_bib35 article-title: miR-129 regulates cell proliferation by downregulating Cdk6 expression publication-title: Cell Cycle doi: 10.4161/cc.9.9.11535 contributor: fullname: Wu – volume: 100 start-page: 9440 year: 2003 ident: 2022061019512851500_bib14 article-title: Statistical significance for genomewide studies publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1530509100 contributor: fullname: Storey – volume: 127 start-page: 265 year: 2006 ident: 2022061019512851500_bib33 article-title: The regulation of INK4/ARF in cancer and aging publication-title: Cell doi: 10.1016/j.cell.2006.10.003 contributor: fullname: Kim |
SSID | ssj0014104 |
Score | 2.3048677 |
Snippet | Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a large EAC... Purpose: Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a... PURPOSE: Chromosomal gain at 7q21 is a frequent event in esophageal adenocarcinoma (EAC). However, this event has not been mapped with fine resolution in a... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 4513 |
SubjectTerms | Adenocarcinoma Adenocarcinoma - diagnosis Adenocarcinoma - enzymology Adenocarcinoma - mortality Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - genetics Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects chromosome 7 Chromosomes, Human, Pair 7 - genetics Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 4 - genetics Cyclin-dependent kinase 6 Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - genetics DNA Copy Number Variations - genetics DNA microarrays Esophageal Neoplasms - diagnosis Esophageal Neoplasms - enzymology Esophageal Neoplasms - mortality Esophagus Female Gastroenterology. Liver. Pancreas. Abdomen Gene Amplification - genetics Gene expression Gene Expression Regulation, Neoplastic Gene Knockdown Techniques Humans Male Medical sciences Middle Aged Oncogenes Pharmacology. Drug treatments Piperazines - pharmacology Prognosis Protein Kinase Inhibitors - pharmacology Pyridines - pharmacology Single-nucleotide polymorphism siRNA Survival Survival Analysis Tumors |
Title | Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21593195 https://search.proquest.com/docview/1093465651 https://pubmed.ncbi.nlm.nih.gov/PMC3390776 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLXKkBASQtwpl8lIvFUpTWIn7uPoug3WDoRaqW-R7TpqHpZObTcEv57vi53b6MPgJWrcxpZyTj_fvnNMyMdUQ6euReTx2A88JofSG6ZwC-RKWSCVjg0KhacX0dmcfV3wRafzs6ku2am-_r1XV_I_qEIZ4Ioq2X9AtqoUCuAz4AtXQBiud8LYuhOf-r3RL1Q4esfuRNtd7zzLoXva4iky3zdrTKZDY1YU5qBgt1AIrHeYKGTl-aUEqzcrEsOLHNkxHnAA0QYxhDqhz9voLF-7OF6aG5TCSo3s2fScd9CqZtyltKvMR5dZxcPPaO0g7YI0mhdsV1m18WNuTCVPnOJEvl4Ht3m9EyC0bC5W4OprXC5W2Pg6QENfFrYDcNwkWtgIp4y7W-NurYb577DPRbEC4Srva231goH1lmzbbF98S07mk0kyGy9m98h9dFDEQxeOv5xX20_ML86drCp00i9o5tPeRlqDmkdXcgsvPrUHo-ybudxOwG2MaGZPyGM3FaFHlldPScfkz8iDqUu2eE5uCnrRU5_ephd19KJyS2t6UUcvCujSil60QS_q6EWznNb0om16vSDzk_FsdOa5Yzo8zThjnoxwnCtTfyh9GeuhGqbLQZoqFYXKlxDx-TIWA4nW_0sRaLQsUzDLl2koY84UD1-Sg3ydm9eEijRUTEUw4RsIZozEPWjD_KUQhplALLukX77n5Mq6sSTFLJaLBIFJEJhkNPoBRQkC0yWHLTSqpwIWwkhcRF3yoYQngcCKu2UyN-vrLaZmhGgmyP0ueWXhqp-GSQD0XbxL4haQ1Q_QtL39TZ6tCvN2aBYdtN7cod235GH9H3pHDnaba_MehsA7dVjQ9Q_-YLPj |
link.rule.ids | 230,314,780,784,885,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+G1+Cyclin-Dependent+Kinases+as+Prognostic+Markers+and+Potential+Therapeutic+Targets+in+Esophageal+Adenocarcinoma&rft.jtitle=Clinical+cancer+research&rft.au=Ismail%2C+Amin&rft.au=Bandla%2C+Santhoshi&rft.au=Reveiller%2C+Marie&rft.au=Toia%2C+Liana&rft.date=2011-07-01&rft.issn=1078-0432&rft.volume=17&rft.issue=13&rft.spage=4513&rft.epage=4522&rft_id=info:doi/10.1158%2F1078-0432.ccr-11-0244&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |